HBV antiviral candidates that shut down virus replication and HBsAg production
Official title: Advancing HBV antivirals that suppress viral replication and HBsAg production
Funded at Door Pharmaceuticals, LLC · NIH-11255456 · Data updated 2026-11-12
A patient-friendly project testing new therapies aimed at stopping hepatitis B virus from multiplying and reducing the surface protein HBsAg to help the immune system clear the virus.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Door Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Bloomington, United States) |
| Project start | July 8, 2026 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $314,363 |
| NIH project number | 1R43AI195101-01 |
| Project ID | NIH-11255456 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with chronic hepatitis B could ultimately be eligible for future trials or therapies stemming from this research.
✕Less likely to help
This specific early-stage project may not directly benefit patients until later development stages or clinical trials.
What this research studies
This project focuses on hepatitis B, a long-term liver infection, and looks for molecules that can both suppress viral replication and lower HBsAg levels. The research will involve identifying molecules that bind HBV components and evaluating their effects in lab models to inform future trials. If successful, these findings could contribute to a functional cure that requires a finite treatment course. While the work is early, patients with chronic HBV could benefit from therapies that enable a stronger immune response against the virus.
Why it matters
Potential benefit: If successful, the work could lead to treatments that help the immune system clear HBV and reduce long-term liver disease.
How similar studies have gone: Previous HBV research has identified targets and strategies that show promise, though translating to cures remains challenging.
Where this research is happening
-
Door Pharmaceuticals, LLC
Bloomington, United States Active
Researchers
- Principal investigator: Nair, Smita — Door Pharmaceuticals, LLC
- Study coordinator: Nair, Smita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.